Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.73 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.64 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.57 |
| ▸ | TSHR | P16473 | 2/20 | 0.57 |
| ▸ | LMNA | P02545 | 2/20 | 0.57 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.57 |
| ▸ | TP53 | P04637 | 1/20 | 0.57 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.57 |
| ▸ | HPGD | P15428 | 2/20 | 0.55 |
| ▸ | GAA | P10253 | 1/20 | 0.55 |
| ▸ | STAT3 | P40763 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29466463 | 0.84 | SMN1; SMN2 (0.73) | SMN1; SMN2ALDH1A1NPSR1TSHRLMNA | |
| SCHEMBL1118436 | 0.84 | SMN1; SMN2 (0.73) | SMN1; SMN2ALDH1A1NPSR1TSHRLMNA | |
| SCHEMBL27896148 | 0.84 | SMN1; SMN2 (1.00) | SMN1; SMN2ALDH1A1NPSR1TSHRLMNA | |
| SCHEMBL24499459 | 0.84 | SMN1; SMN2 (0.73) | SMN1; SMN2ALDH1A1NPSR1TSHRLMNA | |
| SCHEMBL30668842 | 0.80 | SMN1; SMN2 (0.67) | SMN1; SMN2ALDH1A1NPSR1TSHRLMNA | |
| SCHEMBL9298896 | 0.80 | SMN1; SMN2 (0.67) | SMN1; SMN2ALDH1A1NPSR1TSHRLMNA | |
| SCHEMBL7931375 | 0.80 | KMT2A (0.80) | SMN1; SMN2ALDH1A1NPSR1LMNAKDM4E | |
| SCHEMBL15434035 | 0.79 | ALDH1A1 (0.75) | SMN1; SMN2ALDH1A1NPSR1TSHRLMNA | |
| SCHEMBL3309810 | 0.78 | ALDH1A1 (0.73) | SMN1; SMN2ALDH1A1NPSR1LMNAKDM4E | |
| SCHEMBL31570092 | 0.78 | ALDH1A1 (0.73) | SMN1; SMN2ALDH1A1LMNAKDM4EHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110190285-A1 | METHODS OF TREATING A BOTULINUM TOXIN RELATED CONDITION IN A SUBJECT | ABSOLUTE SCIENCE, INC. (US) | 2011-08-04 | — | — | US | disclosed |
| US-20110034521-A1 | COMPOUNDS AND METHODS FOR TREATING ZINC MATRIX METALLOPROTEASE DEPENDENT DISEASES | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2011-02-10 | — | — | US | disclosed |
| WO-2010033360-A1 | METHODS OF TREATING A BOTULINUM TOXIN RELATED CONDITION IN A SUBJECT | 1/3 ABSOLUTE SCIENCE, INC. (US) | 2010-03-25 | — | — | WO | disclosed |
| WO-2009045761-A1 | COMPOUNDS AND METHODS FOR TREATING ZINC MATRIX METALLOPROTEASE DEPENDENT DISEASES | ABSOLUTE SCIENCE, INC. (US) | 2009-04-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110034521-A1 | COMPOUNDS AND METHODS FOR TREATING ZINC MATRIX METALLOPROTEASE DEPENDENT DISEASES | MMP7, MMP3, MMP9 | SMN1; SMN2 313/4885ALDH1A1 496/4885NPSR1 1821/4885 |
| US-20110190285-A1 | METHODS OF TREATING A BOTULINUM TOXIN RELATED CONDITION IN A SUBJECT | NPY5R, RAC3, CPA3 | SMN1; SMN2 120/4885ALDH1A1 2213/4885NPSR1 367/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.